Health

Powerful economic, social and technological trends mean healthcare is one of the fastest growing sectors of the world economy.

The Challenge

  • The global population reached 6.6 billion in 2007, and is predicted surpass 9 billion by 2050.1 This would equate to healthcare spending in 2050 of €8 trillion, compared with €4.4 trillion in 2005.2
  • An ageing population also needs greater healthcare.  Since 1950, the proportion of older persons (aged 60 or older) has been rising steadily, moving from 8% in 1950, to 11% in 2007 and it is expected to reach 22% in 2050.3
  • According to the World Health Organisation (WHO), chronic diseases, are the leading cause of mortality globally, representing 60% of all deaths. As populations in emerging and developing economies continue to adopt western lifestyles and diets, this exacerbates the challenges posed by chronic disease.
  • Communicable diseases,5 are still a major case of death and disability for millions of people globally, the burden falling disproportionately on those in the developing world. More generally, healthcare inequalities still persist globally.

Markets & Drivers

Changing demographic and global disease patterns presents major challenges and opportunities for healthcare management, with the central aim being to deliver better quality healthcare at a lower costs. These pressures, coupled with technological innovation and greater consumer power are leading to increased demand for healthcare goods and services.

  • Increasing emphasis on prevention and early detection can improve healthcare outcomes. WHO states that 80% of premature deaths caused by heart attacks and strokes are preventable. Early detection can also reduce costs, for example early discovery of breast cancer can reduce costs by up to 5 or 6 times compared to late stage treatment.6
  • The healthcare products market in 2007 was worth US$ 629 billion, with medical devices representing 34% of the total and showing sales growth of 6% (2007E – 09E).7
  • The global in vitro diagnostics (IVD)8 market was estimated at US$ 30 billion in 2005, with growth at 6-8% a year.9
  • Within healthcare services, growth is fastest in the speciality/secondary care setting e.g. hospitals.  Estimates for 2005-9E placed CAGR for specialty/secondary at 9%, and primary care at 1%.10

Investment Opportunities

The Health theme focuses on companies whose goods and service enhance, maintain or restore medical health.  This includes companies in the following sub-themes:

  • Prevention & detection – providing solutions to prevent or reduce the likelihood of disease and ill health, and enabling early diagnosis so reducing potential severity
  • Treatment – providing effective treatment, focusing particularly on areas of high unmet medical needs e.g. cancer, HIV/AIDS
  • Access – providing or facilitating access to healthcare by offering key supporting goods and services

Examples of companies within the Health theme include...

  • Intercell (Germany), involved in the research & development of vaccines to treat infectious diseases
  • Pediatrix (USA), a provider of maternal, newnorn and paediatric physician services
  • Smith & Nephew (UK), a healthcare company focusing on orthopaedics, wound care and endoscopy, making products to repair joints, skin, soft tissue and bone

Footnotes

[1] http://www.prb.org/pdf07/07WPDS_Eng.pdf

[2] If growth rates remain stable from 2020. Philips Electronics, ‘2007 Sustainability report’

[3] Philips Electronics, 2007 Sustainability report

[4] Chronic diseases such as heart disease, stroke, cancer, chronic respiratory diseases and diabetes

[5] The most significant in terms of global health burdens include HIV/AIDS, malaria and TB

[6] OCED Healthcare data 2007

[7] Refers to early discovery in Stage 1 Vs late stage 4 treatment, GE healthcare conference presentation, Sept 2007

[8] In vitro diagnostics is the process of diagnosing disease 'outside' of the body. For IVD, a sample is taken from the patient e.g. blood, and sent to a lab for analysis, with the results used to determine a diagnosis and course of treatment for the patient.

[9] UBS, on ‘DiaSorin’, September 2007

[10] S. Adkins, consultant presentation, January 2006

 

Image of doctors instruments

For more information...

Please call us direct on:
0800 88 11 44